These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11366819)

  • 1. IL-2 low dose and treatment interruption: interview with Kendall A. Smith. Interview by John S. James.
    Smith KA
    AIDS Treat News; 1999 Oct; (No 329):1-6. PubMed ID: 11366819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
    Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
    J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 study results in confusion.
    TreatmentUpdate; 1999 Jul; 11(5):4-6. PubMed ID: 11366929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 (IL-2, Proleukin).
    Proj Inf Perspect; 1999 Apr; (27):21-2. PubMed ID: 11366737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
    Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
    Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment interruption; advanced HIV; new ideas: Dr. Cal Cohen interview on retrovirus conference (part 2 or 2). Interview by John S. James.
    Cohen C
    AIDS Treat News; 2003 Apr; (390):2-5. PubMed ID: 12739473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited immune recovery after treatment with antiretrovirals, IL-2; interview with Clifford Lane, M.D. Interview by John S. James.
    Lane C
    AIDS Treat News; 1997 Jun; (No 272):1-5. PubMed ID: 11364426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
    J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
    Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beating HIV at its own game: the success of IL-2.
    Rochon D
    Res Initiat Treat Action; 1998 Dec; 4(7):15-6. PubMed ID: 11366082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS practice issues today: interview with Paul Bellman, M.D. Interview by John S. James.
    Bellman P
    AIDS Treat News; 2000 Apr; (No 340):1-6. PubMed ID: 11367198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. Interview by John S. James.
    Cohen C
    AIDS Treat News; 2004; (407-408):2-4. PubMed ID: 15717379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
    Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
    J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
    Durier C; Capitant C; Lascaux AS; Goujard C; Oksenhendler E; Poizot-Martin I; Viard JP; Weiss L; Netzer E; Delfraissy JF; Aboulker JP; Lévy Y
    AIDS; 2007 Sep; 21(14):1887-97. PubMed ID: 17721096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tale of two trials of HAART interruption.
    STEP Perspect; 1999; 99(1):7. PubMed ID: 11367165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. About interleukin-2.
    Treat Rev; 1995 May; (no 18):6. PubMed ID: 11362594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.